• About
  • Subscribe
  • Advertise
  • Contact
Monday, June 23, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Events Conferences International

New data confirms it’s never too late to start myopia treatment

by rhiannon bowman
March 15, 2022
in International, Myopia, News, Therapies
Reading Time: 2 mins read
A A
Dual-focus soft contact lenses continue to slow the progression of myopia in children over a 6-year period.

Dual-focus soft contact lenses continue to slow the progression of myopia in children over a 6-year period.

Share on FacebookShare on Twitter

Data from a six-year multicentre clinical trial confirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly all children, according to a new peer review paper.

In the longest-running soft contact lens study among children, 90% of myopic eyes responded to MiSight 1 day wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.

Evidence also indicated a sustained slowing of eye growth with no loss of effectiveness over time.

These findings are published in the March 2022 edition of Optometry and Vision Science, the peer review journal of the American Academy of Optometry. The paper, ‘Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial’, is now available via Open Access.

The peer-reviewed six-year paper complements additional CooperVision research demonstrating that the lens slows the rate of myopia progression by half at all observed ages. The data also support that it’s never too late to start treatment, as the lens halves myopia progression in older children as well.

Mr Paul Chamberlain, the study’s principal investigator and CooperVision director of research programs, said the results instil confidence.

“Myopia is a disease that progresses over many years, so demonstrating sustained efficacy is critical,” he said.

“Eyecare professionals can prescribe MiSight 1 day with confidence knowing that the majority of children respond to treatment which lasts.”

The MiSight 1 day study is the world’s longest running soft contact lens clinical trial for myopia management.

This new paper joins a growing body of peer-reviewed research stemming from the CooperVision MiSight 1 day study including Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a 6-year Period (Woods J, et al.) and Axial Length Targets for Myopia Control (Chamberlain P, et al.), as well as the recent Garland W Clay Award winner, A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control (Chamberlain P, et al.).

More reading

Seven-year study shows no myopia control rebound in children wearing MiSight contact lens

WCO and CooperVision develop myopia management resource

CooperVision and Essilor announce JV for acquisition of myopia spectacle lens

Tags: CooperVisionMiSight 1 daymyopia control

Related Posts

Dr William Blase assessing scans obtained on the Optos MonacoPro. Images: Image: California Eye Professionals & Optos.

Early insights into the new Optos MonacoPro

by Staff Writer
June 23, 2025

Optos’ latest system is so new that Insight took its search global to find an ophthalmologist who has installed the...

Collective bargaining on consult times and KPIs are a focus of the group. Image: H_Ko/stock.adobe.com.

Hundreds of optometrists have joined Health Services Union

by Staff Writer
June 19, 2025

Hundreds of Australian optometrists have signed up to the Health Services Union (HSU) in the past few months, according to...

Doug Perkins Specsavers

Specsavers founder Doug Perkins receives top honour from King Charles

by Staff Writer
June 19, 2025

Specsavers co-founder and chair Mr Doug Perkins has been made a Commander of the Order of the British Empire by...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited